Promoter methylation status of multidrug resistance 1 (MDR1) gene in noncancerous gastric mucosa correlates with helicobacter pylori infection and gastric cancer occurrence

Cancer Investigation

Volumn 28, Issue 7, 2010, Pages 711-716

  Tahara, Tomomitsu ^a   Shibata, Tomoyuki ^a   Yamashita, Hiromi ^a   Yoshioka, Daisuke ^a   Hirata, Ichiro ^a   Arisawa, Tomiyasu ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Gastric cancer; MDR1; Methylation

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER; STOMACH MUCOSA;

AGED; DNA METHYLATION; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; RISK; STOMACH NEOPLASMS;

EID: 77954795135     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.483505     Document Type: Article

References (44)

1. Issa, J.P.; Ottaviano, Y.L.; Celano, P.; Hamilton, S.R.; Davidson, N.E.; Baylin, S.B.Methylation of the oestrogen receptor CpG island links aging and neoplasia in human colon. Nat Genet 1994, 4, 536-540.
2. Ahuja, N.; Li, Q.; Mohan, A.L.; Baylin, S.B.; Issa, J.P. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998, 23, 5489-5494.
3. Sato, F.; Harpaz, N.; Shibata, D.; Xu, Y.; Yin, J.; Mori, Y.; Zou, T.T.; Wang, S.; Desai, K.; Leytin, A.; Selaru, F.M.; Abraham, J.M.; Meltzer, S.J. Hypermethylation of the p14 (ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 2002, 62, 1148-1151. (Pubitemid 34160301)
4. Issa, J.P.; Ahuja, N.; Toyota, M.; Bronner, M.P.; Brentnall, T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001, 61, 3573-3577.
5. Bian, Y.S.; Osterheld, M.C.; Fontolliet, C.; Bosman, F.T.; Benhattar, J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002, 122, 1113-1121.
6. Wong, D.J.; Paulson, T.G.; Prevo, L.J.; Galipeau, P.C.; Longton, G.; Blount, P.L.; Reid, B.J. p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61, 8284-8289.
7. Kaneto, H.; Sasaki, S.; Yamamoto, H.; Itoh, F.; Toyota, M.; Suzuki, H.; Ozeki, I.; Iwata, N.; Ohmura, T.; Satoh, T.; Karino, Y.; Satoh, T.; Toyota, J.; Satoh, M.; Endo, T.; Omata, M.; Imai, K. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001, 48, 372-377.
8. Chan, A.O.; Lam, S.K.; Wong, B.C.; Wong, W.M.; Yuen, M.F.; Yeung, Y.H.; Hui,W.M.; Rashid, A.; Kwong, Y.L. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52, 502-506. (Pubitemid 36363400)
9. Maekita, T.; Nakazawa, K.; Mihara, M.; Nakajima, T.; Yanaoka, K.; Iguchi, M.; Arii, K.; Kaneda, A.; Tsukamoto, T.; Tatematsu, M.; Tamura, G.; Saito, D.; Sugimura, T.; Ichinose, M.; Ushijima, T. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006, 12, 989-995.
10. Chan, A.O.; Peng, J.Z.; Lam, S.K.; Lai, K.C.; Yuen, M.F.; Cheung, H.K.; Kwong, Y.L.; Rashid, A.; Chan, C.K.; Wong, B.C. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 2006, 55, 463-468.
11. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-Glycoprotein: from genomics to mechanism. Oncogene 2003, 22, 7468-7485.
12. Chen, C.J.; Clark, D.; Ueda, K.; Pastan, I.; Gottesman, M.M.; Roninson, I.B. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990, 265, 506-514.
13. Fardel, O.; Lecureur, V.; Guillouzo, A. The P-glycoproteinmultidrug transporter. Gen Pharmacol 1996, 27, 1283-1291.
14. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3, 415-428.
15. El-Osta, A.; Kantharidis, P.; Zalcberg, J.R.;Wolffe, A.P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002, 22, 1844-1857.
16. Garcia-Manero, G.; Daniel, J.; Smith, T.L.; Kornblau, S.M.; Lee, M.S.; Kantarjian, H.M.; Issa, J.P. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002, 8, 2217-2224. (Pubitemid 34753593)
17. Worm, J.; Kirkin, A.F.; Dzhandzhugazyan, K.N.; Guldberg, P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 2001, 276, 39990-40000.
18. Tada, Y.; Wada, M.; Kuroiwa, K.; Kinugawa, N.; Harada, T.; Nagayama, J.; Nakagawa, M.; Naito, S.; Kuwano, M. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000, 6, 4618-4627.
19. Takanishi, K.; Miyazaki, M.; Ohtsuka, M.; Nakajima, N. Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma. Oncology 1997, 54, 231-237.
20. Scotlandi, K.; Manara, M.C.; Serra, M.; Benini, S.; Maurici, D.; Caputo, A.; De Giovanni, C.; Lollini, P.L.; Nanni, P.; Picci, P.; Campanacci, M.; Baldini, N. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 1999, 18, 739-746.
21. Kawai, K.; Sakurai, M.; Sakai, T.; Misaki, M.; Kusano, I.; Shiraishi, T.; Yatani, R. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoformspecific monoclonal antibodies. Cancer Lett 2000, 150, 147-153.
22. Van Brussel, J.P.; Jan Van Steenbrugge, G.; Van Krimpen, C.; Bogdanowicz, J.F.; Van Der Kwast, T.H.; Schröder, F.H.; Mickisch, G.H. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001, 165, 130-135.
23. Sullivan, G.F.; Amenta, P.S.; Villanueva, J.D.; Alvarez, C.J.; Yang, J.M.; Hait, W.N. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998, 4, 1393-1403.
24. Tahara, T.; Arisawa, T.; Shibata, T.; Yamashita, H.; Yoshioka, D.; Hirata, I. Effect of promoter methylation of Multidrug resistance 1 (MDR1) gene in gastric carcinogenesis. Anticancer Res 2009, 29, 337-341.
25. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64, 31-49.
26. Dixon, M.F.; Genta, R.M.; Yardley, J.H.; Correa, P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20, 1161-1181.
27. Arisawa, T.; Tahara, T.; Shibata, T.; Nagasaka, M.; Nakamura, M.; Kamiya, Y.; Fujita, H.; Takagi, T.; Hasegawa, S.;Wang, F.Y.; Hirata, I.; Nakano, H. Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach. J Gastroenterol Hepatol 2007, 22, 943-948.
28. Tahara, T.; Arisawa, T.; Shibata, T.; Wang, F.Y.; Nakamura, M.; Sakata, M.; Nagasaka, M.; Takagi, T.; Kamiya, Y.; Fujita, H.; Nakamura, M.; Hasegawa, S.; Iwata, M.; Takahama, K.; Watanabe, M.; Hirata, I.; Nakano, H. Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 2007, 75, 54-61.
29. Jemal, A.; Tiwari, R.C.; Murray, T.; Ghafoor, A.; Samuels, A.;Ward, E.; Feuer, E.J.; Thun, M.J. American Cancer Society. Cancer statistics 2004. CA Cancer J Clin 2004, 54, 8-29.
30. Uemura, N.; Okamoto, S.; Yamamoto, S.; Matsumura, N.; Yamaguchi, S.; Yamakido, M.; Taniyama, K.; Sasaki, N.; Schlemper, R.J. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345, 784-789.
31. Ekstrom, A.M.; Held, M.; Hansson, L.E.; Engstrand, L.; Nyren, O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001, 121, 784-791.
32. Forman, D.;Weeb, P.; Parsonnet, J.H. H. pylori and gastric cancer. Lancet 1994, 343, 243-244.
33. Uemura, N.; Mukai, T.; Okamoto, S.; Yamaguchi, S.; Mashiba, H.; Taniyama, K.; Sasaki, N.; Haruma, K.; Sumii, K.; Kajiyama, G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997, 6, 639-642.
34. Wong, B.C.; Lam, S.K.;Wong,W.M.; Chen, J.S.; Zheng, T.T.; Feng, R.E.; Lai, K.C.; Hu, W.H.; Yuen, S.T.; Leung, S.Y.; Fong, D.Y.; Ho, J.; Ching, C.K.; Chen, J.S.; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a highrisk region of China: a randomized controlled trial. JAMA 2004, 291, 187-194.
35. Hosokawa, O.; Tsuda, S.; Kidani, E.; Watanabe, K.; Tanigawa, Y.; Shirasaki, S.; Hayashi, H.; Hinoshita, T. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy 1998, 30, 721-723.
36. Kang, G.H.; Lee, H.J.; Hwang, K.S.; Lee, S.; Kim, J.H.; Kim, J.S. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003, 163, 1551-1556.
37. Correa, P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995, 19(Suppl. 1), S37-S43.
38. Bao, J.J.; Lee, B.P.; Stephens, L.C.; Sahin, A.A.; Van, N.T.; Johnston, D.A.; Ou, C.N.; Kuo, M.T. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis B virus transgenicmice lacking MDR1a-encoded P-glycoprotein. Mol Carcinog 2000, 29, 103-111.
39. Sanchez-Carbayo, M.; Belbin, T.J.; Scotlandi, K.; Prystowsky, M.; Baldini, N.; Childs, G.; Cordon-Cardo, C. Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes. Lab Invest 2003, 83, 507-517.
40. Li, D.; Jang, S.H.; Kim, J.; Wientjes, M.G.; Au, J.L. Enhanced druginduced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res 2003, 20, 45-50.
41. Gan, Y.; Wientjes, M.G.; Au, J.L. Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin Cancer Res 1998, 4, 2949-2955.
42. Karwatsky, J.; Lincoln, M.C.; Georges, E. A mechanism for Pglycoprotein- mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 2003, 42, 12163-12173.
43. Burger, H.; Foekens, J.A.; Look, M.P.; Meijer-van Gelder, M.E.; Klijn, J.G.; Wiemer, E.A.; Stoter, G.; Nooter, K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003, 9, 827-836.
44. Sinicrope, F.A.; Hart, J.; Brasitus, T.A.; Michelassi, F.; Lee, J.J.; Safa, A.R. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994, 74, 2908-2917